Hepatitis C virus (HCV) antiviral therapy in liver transplant candidates with decompensated cirrhosis may result in long-term improvement in liver function, giving as many as 1 in 3 patients the possibility of being taken off the transplant list, according to a study published in Liver International.

Many people infected with HCV who have decompensated cirrhosis are on the waiting list for liver transplantation. A previous study by the European Liver and Intestine Transplant Association, however, showed that treatment with second-generation direct-acting antivirals (DAAs) resulted in nearly 25% of patients being taken off the transplant list because of clinical improvement.

Read More…https://www.infectiousdiseaseadvisor.com/hepatitis-advisor/hcv-liver-transplant-outcomes-after-delisting/article/772610/